FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan
      ·

      gildtfc

      ·

      Truist Increases Gilead Price Target to $155

      Truist analyst Gregory Renza has raised the price target for Gilead Sciences, Inc. to $155 from a previous target of $152. The firm maintains a Buy rating on Gilead shares as part of a broader analysis ahead of the company's upcoming Q1 earnings report.

      The adjustment in the price target reflects a positive outlook on the biotech sector, with analysts noting a decrease in market reactivity to regulatory and policy changes. Additionally, there has been an increase in deal-making activity within the industry, which could contribute to growth and momentum as the year progresses, particularly leading into the mid-term elections.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud